93 results on '"Eichinger, Katy"'
Search Results
52. Evaluation of Postural Control and Falls in Individuals with Myotonic Dystrophy Type 1
53. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
54. 9 - Physical Therapy for Neuromuscular Conditions
55. Transcriptome alterations in myotonic dystrophy skeletal muscle and heart
56. Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1‐year follow‐up study
57. Muscle Strength and Function Measures in a Multicenter Study of Myotonic Dystrophy Type 1 (DM1): Baseline Impairment and Test-Retest Agreement over 3 Months (P5.455)
58. Facioscapulohumeral muscular dystrophy functional composite outcome measure
59. Recruiting for an International Rare Disease Clinical Trial Readiness Study during the COVID‐19 pandemic: Challenges and solutions.
60. Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy
61. The Facioscapulohumeral Dystrophy Composite Outcome Measure: 1 Year Findings (P1.117)
62. Evaluation of Postural Control and Falls in Individuals with Myotonic Dystrophy Type 1 (P2.133)
63. The Myotonic Dystrophy Health Index: Correlations with Clinical Tests and Patient Function
64. Prospective Study of Muscle Cramps in Charcot Marie Tooth Disease
65. Transcriptome alterations in myotonic dystrophy skeletal muscle and heart.
66. Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy
67. Patient Reported Falls and Balance Confidence in Individuals with Charcot-Marie-Tooth Disease
68. Electrical impedance myography in facioscapulohumeral muscular dystrophy
69. Reliability and Validity of the 6 Minute Walk Test in Individuals with Facioscapulohumeral Dystrophy (P3.120)
70. Electrical Impedance Myography Is Reliable and Correlates to Measures of Facioscapulohumeral Muscular Dystrophy Disease Severity (S36.006)
71. Study Design of a Phase 1/2a Trial with ISIS-DMPKRx for the Treatment of Myotonic Dystrophy Type 1 (P3.167)
72. Three Year Natural History of Motor Impairment in Myotonic Dystrophy Type 1 (DM1) (P1.130)
73. Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS.
74. Myotonic dystrophy health index: Correlations with clinical tests and patient function
75. An Open-Label Trial of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-1/rhIGFBP-3) in Myotonic Dystrophy Type 1
76. Reliability and Validity of of the FSHD Composite Outcome Measure (P3.161)
77. What does the Six Minute Walk Test Reflect in Myotonic Dystrophy Type 1 (DM1)? (P3.166)
78. Physical Activity Profile and Barriers to Physical Activity in Individuals with Myotonic Dystrophy (P5.084)
79. Contributors
80. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV1.1 calcium channel
81. Combination therapy with nusinersen and AVXS-101 in SMA type 1.
82. Contributors
83. Needs management in families affected by childhood-onset dystrophinopathies.
84. SupplementalFile1_Table_1 – Supplemental material for Needs management in families affected by childhood-onset dystrophinopathies
85. SupplementaryFile3_Managed_Frequencies – Supplemental material for Needs management in families affected by childhood-onset dystrophinopathies
86. SupplementaryFile2_Needs_Frequencies – Supplemental material for Needs management in families affected by childhood-onset dystrophinopathies
87. SupplementaryFile3_Managed_Frequencies – Supplemental material for Needs management in families affected by childhood-onset dystrophinopathies
88. Additional file 1: of Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study
89. SupplementalFile1_Table_1 – Supplemental material for Needs management in families affected by childhood-onset dystrophinopathies
90. Additional file 1: of Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study
91. SupplementaryFile2_Needs_Frequencies – Supplemental material for Needs management in families affected by childhood-onset dystrophinopathies
92. 9 - Physical Therapy for Neuromuscular Conditions
93. Contributors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.